Korean Market
EXCH
Voronoi
★

Notice of Investor Relations Meeting: Communication of Business Status and Pipeline Progress with Domestic Institutional Investors

 
EXCH
Voronoi
★

Voronoi Receives Approval for Amendment of Phase 1/2 Trial of VRN110755 in EGFR-mutant NSCLC, Expanding to Australia for Global Development

 
OWNR
Voronoi
★

Major shareholder Hyun-tae Kim extends stock-backed loans, maintains 40.92% stake... management stability confirmed

 
EXCH
Voronoi
★

VRN110755 Phase 1/2 Clinical Trial Amendment Filed and Australian HREC Submission Completed... Global Expansion Underway, Neutral Impact on Shareholder Value

 
PERI
Voronoi
★

Voronoi Q1 2026: Operating loss of 22B won, positive clinical progress

 
EXCH
Voronoi
★

Yuanta Securities Corporate Day IR Participation

 
MATR
Voronoi
★

Disclosure of Designation of Call Option Exercise on Convertible Bonds